Date: 27 Aug 2011

UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



The aim of this work as to investigate the photochemical interaction used in corneal crosslinking (CXL) as the primary therapy for bacterial keratitis.


A prospective non-randomized study was conducted including 16 patients with a clinical diagnosis of bacterial keratitis. No patient had any prior antibiotic treatment for the current infection. Photography and microbial culturing of the infected cornea were performed. Riboflavin was topically administered for 20 min and ultraviolet light (UVA) exposure settings for treatment of keratoconus were used. After the procedure, clinical examinations were done at least once daily until signs of improvement had been established. The frequency of examinations was thereafter reduced. Antibiotic therapy was initiated if infectious progression was suspected. The trial was registered at (no: 21432643).


All eyes responded to the photochemical treatment with improvement in symptoms and signs of reduced inflammation. Epithelial healing was achieved in all cases. Antibiotic administration was necessary in two cases. One patient required a human amniotic membrane transplant.


This trial illustrates that photosensitization of riboflavin using UVA at 365 nm has the potential to induce healing in patients with microbial keratitis. The results from the treatment of these 16 patients with corneal ulcers indicate that UVA-riboflavin photochemical therapy merits a controlled study in order to assess its efficacy and safety compared to antibiotics.

Meeting presentation: This work was in part presented at the Vth International Congress of Corneal Crosslinking, December 4–5, 2009, Leipzig, Germany, the Nordic Congress of Ophthalmology, August 4–7, 2010, Reykjavik, Iceland, and the VIth International Congress of Corneal Crosslinking, January 21–22, Milan, Italy.